News & Updates

In pregnant women who present with first-trimester vaginal bleeding, treatment with progesterone throughout pregnancy does not appear to be beneficial in terms of lowering the risk of miscarriage or premature delivery, according to PREEMPT trial presented at this year’s American College of Obstetricians and Gynecologists (ACOG 2022) meeting.

The combination of ipilimumab and nivolumab may provide a progression-free survival (PFS) benefit in patients with metastatic or unresectable melanoma who did not respond to anti-PD-1/anti-PD-L1 therapy, according to a small study presented at AACR 2022.

In solid organ transplant recipients with moderate symptoms of SARS-CoV-2 infection, early administration of a 3-day remdesivir course appears to effectively prevent COVID-19-related hospitalization as well as the clinical worsening of those who are hospitalized, according to a study.

Pregnant women with preconception venous thromboembolism (VTE) who have no exposure to any anticoagulant and those on low-molecular-weight heparin (LMWH) have the lowest risk of foetal adverse outcomes, reveals a study, which supports the recommendation of LMWH during pregnancy.

The addition of the monoclonal anti-interleukin-1β antibody canakinumab to the standard of care (SoC) regimen of platinum doublet chemotherapy and pembrolizumab in the first-line setting did not improve progression-free survival (PFS) or overall survival (OS) in patients with advanced non-small-cell lung cancer (NSCLC), results of the phase III CANOPY-1 trial showed.